Janney Montgomery Scott upgraded shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) from a neutral rating to a buy rating in a research report report published on Monday. They currently have $65.00 price target on the stock, up from their previous price target of $30.00.

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Several other equities analysts also recently weighed in on SRPT. Oppenheimer Holdings Inc. reissued a buy rating and issued a $60.00 price target on shares of Sarepta Therapeutics in a research note on Sunday, July 17th. Piper Jaffray Cos. reissued a sell rating and issued a $6.00 price target on shares of Sarepta Therapeutics in a research note on Saturday, June 4th. Robert W. Baird reissued an outperform rating and issued a $23.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, May 26th. Vetr downgraded shares of Sarepta Therapeutics from a buy rating to a strong sell rating and set a $17.28 target price on the stock. in a research note on Wednesday, June 8th. Finally, Cowen and Company reaffirmed a hold rating on shares of Sarepta Therapeutics in a research note on Thursday, May 26th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $51.01.

Sarepta Therapeutics (NASDAQ:SRPT) opened at 56.22 on Monday. The company’s 50 day moving average is $29.05 and its 200-day moving average is $21.62. The stock’s market cap is $2.69 billion. Sarepta Therapeutics has a 1-year low of $8.00 and a 1-year high of $58.87.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same period in the previous year, the firm earned ($0.87) EPS. Equities research analysts forecast that Sarepta Therapeutics will post ($4.17) earnings per share for the current fiscal year.

In related news, CEO Edward M. Md Kaye sold 24,557 shares of the company’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total value of $736,710.00. Following the completion of the sale, the chief executive officer now owns 76,983 shares in the company, valued at approximately $2,309,490. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Jayant Aphale sold 35,000 shares of the company’s stock in a transaction on Monday, September 19th. The shares were sold at an average price of $50.00, for a total transaction of $1,750,000.00. Following the completion of the sale, the vice president now owns 21,490 shares of the company’s stock, valued at approximately $1,074,500. The disclosure for this sale can be found here. Company insiders own 10.90% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in SRPT. Teacher Retirement System of Texas increased its stake in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock valued at $115,000 after buying an additional 724 shares during the period. Advisor Group Inc. acquired a new stake in Sarepta Therapeutics during the second quarter valued at approximately $154,000. Quantitative Systematic Strategies LLC acquired a new stake in Sarepta Therapeutics during the second quarter valued at approximately $211,000. National Planning Corp increased its stake in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares during the period. Finally, First Allied Advisory Services Inc. increased its stake in Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock valued at $245,000 after buying an additional 800 shares during the period. Hedge funds and other institutional investors own 72.09% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.